193 related articles for article (PubMed ID: 9579771)
1. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M
J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Lacourcière Y
Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
Tikkanen I; Omvik P; Jensen HA
J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
[TBL] [Abstract][Full Text] [Related]
6. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
[TBL] [Abstract][Full Text] [Related]
7. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
[TBL] [Abstract][Full Text] [Related]
9. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
[TBL] [Abstract][Full Text] [Related]
11. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
13. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Neutel JM; Germino FW; Smith D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
[TBL] [Abstract][Full Text] [Related]
14. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
Byyny RL; Merrill DD; Bradstreet TE; Sweet CS
Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074
[TBL] [Abstract][Full Text] [Related]
15. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
Zanchetti A; Omboni S
Am J Hypertens; 2001 Feb; 14(2):129-34. PubMed ID: 11243303
[TBL] [Abstract][Full Text] [Related]
16. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
Ruff D; Gazdick LP; Berman R; Goldberg AI; Sweet CS
J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
[TBL] [Abstract][Full Text] [Related]
19. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
Raskin P; Guthrie R; Flack J; Reeves R; Saini R
J Hum Hypertens; 1999 Oct; 13(10):683-7. PubMed ID: 10516738
[TBL] [Abstract][Full Text] [Related]
20. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
